Skip Navigation

  1. Acerca de Nosotros
    1. Visión General
    2. Historia
    3. Oficinas
  2. Nuestra Experiencia
    1. Áreas de Trabajo
      1. Patentes
      2. Marcas
      3. Derecho de Autor
      4. Derecho Corporativo y Mercantil
      5. Litigio de Propiedad Intelectual y Resolución Alternativa de Disputas
      6. Práctica Regulatoria
      7. Otorgamiento de Licencias, Transferencia de Tecnología y Franquicias
      8. Anti-Piratería, Anti-Falsificación & Aplicación
    2. Grupos de la Industria
      1. Grupo de Abogados en Medios, Deportes y Entretenimiento
      2. Grupo de Abogados e Ingenieros en Ciencias de la Vida
  3. Nuestra Gente
    1. Socios
      1. Sergio L. Olivares, Sr. † (1931-2010)
      2. Sergio L. Olivares, Jr.
      3. Luis C. Schmidt
      4. César Ramos, Jr.
      5. Antonio Belaunzarán
      6. Gustavo A. Alcocer
      7. Alejandro Luna
      8. Alonso Camargo
      9. Daniel Sánchez
      10. Abraham Diaz
    2. Asociados (A - M)
      1. Osvaldo Amaral
      2. Armando Arenas
      3. Sofía Arroyo
      4. Guillermo Ballesteros
      5. Georgina Flores
      6. Pedro Herrera
    3. Asociados (N - Z)
      1. Mauricio Narváez
      2. Víctor Ramírez
      3. Sergio Rangel
      4. Maria del Carmen Sada
      5. Juan Luis Serrano
      6. Guillermo Treviño
    4. Abogados / Ingenieros
      1. Emilio Albarrán
      2. Agustín Azcatl
      3. Alejandra Badillo
      4. Ignacio Burgoa
      5. Fernando Calderón
      6. Martha Celis
      7. Erwin Cruz
      8. Fernanda Díaz
      9. Maria Fenton
      10. Luz Elena Elías
      11. 15 more items...
    5. Administración de la firma
    6. Directorio
  4. Conocimiento & Recursos
    1. Artículos y Estudios de Casos
      1. Artículos sobre Marcas
        1. International Comparative Legal Guide: Trademarks 2013
        2. Errores en las solicitudes de marcas
        3. La Suprema Corte: todo inidividuo puede registrar una marca
        4. Use requirements
        5. Approach to composite marks changed, again
        6. Life Sciences Handbook 2011 - Country Q&A
        7. Mexico should accept secondary meaning
        8. Getting the Deal Through - Trademarks 2011
        9. Pharmaceutical Trademarks 2010/2011 - A Global Guide
        10. No legal basis for banning names derived from INNs
        11. 46 more items...
      2. Artículos sobre Patentes
        1. Ampliación de la Protección de Diseños Industriales
        2. Mexican Linkage Gazette April 2011
        3. Mexico issues regulations to approve biologic drugs
        4. Latin America Roundtable
        5. New regulations pending
        6. The International Comparative Guide
        7. Marketing authorization for pharmaceutical
        8. Approval of follow-on biologics in Mexico
        9. Patent Prosecution Highway in Mexico
        10. Life Sciences Handbook 2011 - Country Q&A
        11. 36 more items...
      3. Artículos sobre Derecho de Autor
        1. Publicidad en redes sociales
        2. Technology challenges digital rights
        3. Exceptions to copyright protection and the permitted uses of copyright works in the hi-tech and digital sectors
        4. Derechos sobre producción audiovisual
        5. How Latin America tackles cutting-edge IP issues
        6. Copyright Litigation 2010
        7. Legislation and enforcement - Copyrights 2010
        8. Valuing folklore
        9. Protecting novel ideas
        10. Mexico's fair use balancing act
        11. 97 more items...
      4. Artículos sobre Derecho Corporativo
        1. Mexico issues Personal Data Protection Rules
        2. A practical cross-border
        3. New registry for security interests
        4. The International Comparative Legal Guide to: Merger Control 2011
        5. The International Comparative Legal Guide to: Merger Control 2010
        6. Due diligence issues to consider in M&A
        7. Income expectations in licensing
        8. The reasons for valuation
        9. Amendments proposed to franchise regulation
      5. Artículos sobre Litigio y RAD
        1. Scope of new specialised courts widened
        2. Reform of preliminary injunctions
        3. Mexican Patent Office excludes Formulation Patents from Linkage Gazette
        4. Mexico gets ready to approve biocomparable drugs
        5. Mexico's hotel for the stars highlights power in the name
        6. Supreme Court upholds the worth of formulation patents
        7. Getting the Deal Through - Patents 2010
        8. Getting the Deal Through Trademarks 2010
        9. Trademark enforcement
        10. Venues for appealing IMPI decisions
        11. 15 more items...
      6. Artículos sobre Derecho Regulatorio
        1. La NOM 257 modifica el sistema de vinculación de patentes de medicamentos en México
        2. Recientes enmiendas a la Ley Federal de Protección al Consumidor
        3. Enmiendas en la Ley Federal de Protección al Consumidor
        4. Mexico issues Personal Data Protection Rules
        5. New Regulations Pending
        6. Marketing authorization for pharmaceutical products to foreign applicants
        7. Data Package Exclusivity (DPE)
        8. Supreme Court upholds the worth of formulation patents
        9. Pharmaceutical trademarks
        10. Framework for biotherapeutic products established
        11. 5 more items...
      7. Artículos sobre Licencias y Transferencia de Tecnología
        1. Creating a secure franchise system
      8. Artículos sobre Anti-piratería y Anti-falsificación
        1. New register against counterfeits
        2. Beat the counterfeiters in Mexico
        3. Battling counterfeits through Customs
        4. Getting the Deal Through Trademarks 2010
        5. Enforcing plant variety rights in Mexico
        6. Pharmaceutical Trademarks 2009
        7. Internet Issues
        8. Anti-counterfeiting 2009
        9. Vegetal variety rights enforced
        10. New Customs rules lead to seizures
        11. 4 more items...
      9. Artículos en relación con Medios, Deportes y Entretenimiento
        1. Publicidad en redes sociales
        2. Whither Rental Rights?
        3. Improved protection for personalities
      10. Artículos en relación con Ciencias de la Vida
        1. Latin America Roundtable
        2. New regulations pending
        3. The International Comparative
        4. Approval of follow-on biologics in Mexico
        5. Global Pharmaceutical Linkage Regulations:
        6. Life Sciences Handbook 2011 - Country Q&A
        7. Supreme Court upholds the worth of formulation patents
        8. Repercussions expected on medicine advertising campaign in Mexico
        9. Framework for biotherapeutic products established
        10. Pharmaceutical Trademarks 2009
        11. 1 more item...
    2. Noticias
      1. La Propiedad Intelectual en el Entorno Digital
      2. Intellectual Property: Past & Future
      3. Iniciativa de ley para reducir la vigencia de patentes de medicamentos
      4. Entrevista a Alejandro Luna sobre "La Innovación y biotecnología"
      5. México firma el Acuerdo Comercial Anti-falsificación (ACTA)
      6. Modificaciones a la Ley de Propiedad Intelectual
      7. Se realizan enmiendas a la Ley Federal de Protección al Consumidor
    3. Gacetas
      1. Mexican Linkage Gazette March 2013
      2. Mexican Linkage Gazette December 2012
      3. Mexican Linkage Gazette November 2012
      4. Mexican Linkage Gazette December 2011
      5. Mexican Linkage Gazette April 2011
  5. Oficinas
  6. Eventos
  7. Contacto

Español » Conocimiento & Recursos » Artículos y Estudios de Casos » Artículos sobre Patentes » Data Package Exclusivity (DPE)

Data Package Exclusivity (DPE)

In previous newsletters regarding Data Package Exclusivity (DPE) in Mexico we highlighted that the domestic law was silent in the recognition of DPE rights. We also commented that in January 2008, the Mexican Health Regulations were amended concerning generic medications, eliminating the requirement to prove safety and efficacy for generics, which was substituted by the need to prove interchangeability.

In short, in 2008 the regulations were modified to implement an abbreviated approval procedure for generic drugs, on the basis of bioequivalence and bioavailability studies, without setting forth any provisions containing a non-reliance period as established in the international treaties such as NAFTA and TRIPS.

Based on the hierarchy of international treaties established in the Mexican Constitution, where international treaties approved by the Mexican Senate supersede Federal Laws, our firm structured a litigation strategy to secure recognition of DPE rights in Mexico.  Although we have obtained valuable preliminary injunctions, ordering the regulatory agency to refrain from grant marketing authorizations relying directly or indirectly in the dossier of the innovator or the so-called product of reference, these cases remain under prosecution and are pending to be decided on their merits by the courts.   

The issue has been discussed in many forums, highlighting the limitations of our domestic law, the possibility that the amendments to the Health Law in 2008 disregarding DPE rights could be considered as a contradiction with the international treaties, and that litigating the recognition of these rights is an unnecessary burden for individuals.  In consequence this past February, 2011, a publication was made in the Gazette of the Congress, containing a proposal of amendment to the Health Law to fully recognize DPE rights in the Mexican Health Law.   The proposal reads as follows:

“Art. 376….

For the purposes of this article and concerning interchangeable generics for allopathic medicines, the corresponding marketing authorizations can be only granted after a period of five years running from the date of granting of the medicament considered as innovator or product of reference; unless that the applicant is be the titleholder of the marketing authorization for the innovator or reference product or, applicant has obtained an express authorization from the titleholder.”

The following issues arise from this proposal:

·         The word “interchangeable” referring to generic drugs should be removed from the article, as in 2008 the amendments to the Health Regulations eliminated the previously existing distinction between generics and interchangeable generics.

·         The proposal does not make specific distinctions for protection of new chemical entities, formulations and new indications.

·         The proposal limits the scope of protection of DPE to five years while NAFTA establishes the five year period as a minimum.

·         The proposal seems to be also limited to allopathic medicines of chemical nature, as there is no specific mention to biologic drugs.  In other jurisdictions establishing DPE rights, biologic drugs obtain a longer protection period.

·         The Health Regulations should be also immediately amended and modified to coincide, clarify and accomplish the amendments of the Health Law.

 

In short, the proposal is highly positive and welcomed, as it would put an end to the contradiction of the domestic law with international treaties and would grant certainty and incentives to investors, companies conducting clinical trials and developers of innovative medicines.   It will be important to monitor lobby efforts before the Mexican Congress, in a scenario close to the next presidential elections in Mexico and facing the opposition to this proposal by some sectors of the pharma industry.

Mexico intends to pass a new law to fully recognize DPE rights in the domestic law.

por Alejandro Luna